Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277249 | 0.83 | USP2 (0.42) | SMN1; SMN2USP2MAPTRECQLUSP30 | |
| SCHEMBL3279440 | 0.82 | MAPK1 (0.47) | GPR119RORCDDB1CRBNSMN1; SMN2 | |
| SCHEMBL3276330 | 0.81 | PIK3CD (0.44) | GPR119SMN1; SMN2USP2MAPTRIPK1 | |
| SCHEMBL3276664 | 0.80 | USP2 (0.39) | GPR119SMN1; SMN2USP2MAPTRECQL | |
| SCHEMBL3276368 | 0.78 | MAPK1 (0.46) | GPR119DDB1CRBNSMN1; SMN2USP2 | |
| SCHEMBL3281416 | 0.78 | MAPK1 (0.46) | GPR119DDB1CRBNSMN1; SMN2USP2 | |
| SCHEMBL3279949 | 0.77 | MAPK1 (0.45) | GPR119DDB1CRBNSMN1; SMN2USP2 | |
| SCHEMBL3276194 | 0.77 | GPR119 (0.42) | GPR119SMN1; SMN2USP2RIPK1 | |
| SCHEMBL9902986 | 0.76 | USP2 (0.41) | GPR119SMN1; SMN2USP2MAPTRECQL | |
| Hydrochloric Acid SCHEMBL11893474 | 0.75 | USP2 (0.40) | GPR119SMN1; SMN2USP2MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123644-B1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8247403-B2 | Benzoxazepine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2123644-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | HTR2C, HTR5A, HTR2B | GPR119 96/4885RORC 1472/4885DDB1 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.